Evidence map›Paper›PMID 41199355›Full record

ArticleJournal of cannabis research2025

The impact of tetrahydrocannabinol on central pain modulation in chronic pain: a randomized clinical comparative study of offset analgesia and conditioned pain modulation in fibromyalgia.

Yara Agbaria, Raz Preger, Valerie Aloush, Jacob N Ablin, Haggai Sharon, Giris Jacob

Registry-linked trialAbstract read
In one paragraph

Article in Journal of cannabis research, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT05644054 (The Impact of THC on Pain Modulation in Fibromyalgia), which is not on this map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT05644054 naunknown statusnot on this map

The Impact of THC on Pain Modulation in Fibromyalgia: A Cross-Over, Randomized, Double-Blind Placebo-Controlled Study

TypeinterventionalSponsorTel Aviv Medical CenterRan2023 to 2024Enrolled40ConditionsFibromyalgia, PrimaryArmsTHC, Placebo
3 · Its place in the literature

Who cites it

3 citing papers in PubMed.

  1. Article
  2. Article
  3. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors.

Yara AgbariaSchool of Medicine, Gray Faculty of Medical and Health Sciences, Tel Aviv University, Tel Aviv, Israel.ORCID http://orcid.org/0009-0003-4356-1211
Raz PregerSagol School of Neuroscience, Tel Aviv University, Tel Aviv, Israel.
Valerie AloushSchool of Medicine, Gray Faculty of Medical and Health Sciences, Tel Aviv University, Tel Aviv, Israel.
Jacob N AblinSchool of Medicine, Gray Faculty of Medical and Health Sciences, Tel Aviv University, Tel Aviv, Israel.
Haggai Sharon *School of Medicine, Gray Faculty of Medical and Health Sciences, Tel Aviv University, Tel Aviv, Israel. haggaisharon@gmail.com.
Giris Jacob *School of Medicine, Gray Faculty of Medical and Health Sciences, Tel Aviv University, Tel Aviv, Israel. jacob.giris@gmail.com.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundTetrahydrocannabinol (THC) has shown efficacy in alleviating chronic pain, particularly in disorders characterized by central sensitization. Offset analgesia (OA) and conditioned pain modulation (CPM) are key biomarkers used to evaluate central pain modulation. This study aimed to compare the effects of THC on OA and CPM in fibromyalgia syndrome (FMS), a prototypical condition of central sensitization.

methodsIn a randomized, double-blind, placebo-controlled crossover design, 23 FMS patients participated in two experimental sessions. Each session included the McGill Pain Questionnaire, visual analogue scale (VAS) assessments, and evaluations of OA and CPM, conducted both before and after sublingual administration of either THC (0.2 mg/kg) or placebo.

resultsTHC significantly reduced spontaneous pain ratings on the McGill scale compared to both baseline and placebo (P = 0.01 and P = 0.02, respectively). THC also significantly enhanced OA relative to baseline and placebo (P = 0.04 and P = 0.008), while no effect was observed on CPM (P = 0.27). Notably, baseline OA magnitude significantly predicted THC-induced pain relief (R² = 0.404, P = 0.003), whereas CPM did not show a significant association (P = 0.121).

conclusionsThis is the first study to evaluate THC’s distinct effects on central pain modulation using both OA and CPM. THC selectively enhanced OA without influencing CPM, highlighting differential neural mechanisms underlying these paradigms. Furthermore, OA predicted treatment response, suggesting its potential as a biomarker for personalized cannabinoid-based therapies in FMS and other central sensitization disorders.

trial registrationThe study was prospectively registered on ClinicalTrials.gov (ID: NCT05644054) at 1.1.2023. Further details can be found at: https://clinicaltrials.gov/study/NCT05644054?locStr=Israel&country=Israel&cond=fibromyalgi215a%20&intr=THC&aggFilters=status:not%20rec&rank=1 .

Indexed as

Central sensitizationConditioned pain modulationFibromyalgiaOffset analgesiaPain reliefTetrahydrocannabinol

Identifiers

PMID41199355
PMCPMC12590702

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.